Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A

Inclusion Criteria: * Male, age at least 18 years at the time of signing informed consent * History of more than 150 exposure days to any factor VIII products * Subjects with the diagnosis of congenital haemophilia A with factor VIII activity below 1%, based on medical records Exclusion Criteria: * Known history of factor VIII inhibitors * Inhibitors to factor VIII (above or equal to 0.6 BU (Bethesda units)) at screening measured by the Nijmegen modified Bethesda method * Known congenital or acquired coagulation disorders other than haemophilia A * Previous participation in pharmacokinetic sessions with turoctocog alfa in another trial